Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Genomic Revolution ETF (ARKG) vs BridgeBio Pharma Inc (BBIO) Price & Performance

ARK Genomic Revolution ETFTrade
BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

ARK Genomic Revolution ETF vs BridgeBio Pharma Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.5, while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.

ARKGBBIO
Sector
Sector/ThematicHealth
52-Week High
$44.55$90.17
52-Week Low
$24.02$47.29
Market Cap
$16.61B
Enterprise Value
$18.16B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Genomic Revolution ETF

ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.

The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.

BridgeBio Pharma Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO